Top tier pharma will see lacklustre growth after tough 2012
This article was originally published in Scrip
Top tier companies are expected to see a 2% decline in total sales in 2012 before posting lacklustre growth through to 2017, according to a half-year update report from Datamonitor which extrapolates ahead from companies' most recently reported results (Half Year 2012: Big pharma update). Key patent expiries of best selling drug and concomitant increases in generic competition will, the report says, prompt a $5.7 billion decline in the total 2012 sales of the leading 12 pharma companies at $390.5 billion. By 2017, aggregate sales at the top tier companies are forecast to be back to $392.7 billion.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.